$0.22 0.00 (0.28%) Rexahn Pharmaceuticals Inc - NYSE Amex Equities

Sep. 23, 2016 | 04:00 PM
Last Trade: 0.22
Trade Time: Sep 23 04:00 PM Eastern Daylight Time
Change: +0.00 (0.28%)
Prev Close: 0.22
Open: 0.23
Bid: 0.21
Ask: 0.22
  1. No results found.
  1. Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study

    Benzinga | Jan. 11, 2016 | 09:06AM EST
  2. Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin(R) at the 14th International Kidney Cancer Symposium

    Benzinga | Nov. 5, 2015 | 09:02AM EST
  3. Rexahn Pharmaceuticals Presents Preliminary Clinical Data for Supinoxin(TM) and RX-3117 Oncology Programs at the European Cancer Congress 2015

    Benzinga | Sep. 28, 2015 | 09:02AM EST
  4. Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

    Benzinga | Jul. 14, 2015 | 09:04AM EST
  5. Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for Cancer Research Annual Meeting

    Benzinga | Apr. 20, 2015 | 09:03AM EST
  6. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  7. Rexahn Receives A Notice of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform

    Benzinga | Sep. 3, 2014 | 09:08AM EST
  8. Rexahn Presents Data from Preclinical Studies of RX-21102

    Benzinga | Apr. 21, 2014 | 09:00AM EST
  9. Rexahn Pharmaceuticals to Present Data at American Association for Clinical Research Annual Meeting

    Benzinga | Apr. 2, 2014 | 09:00AM EST
  10. Mid Morning Gainers for March 11th, 2014

    Benzinga | Mar. 11, 2014 | 11:20AM EST
  11. Morning Movers for Feb. 26, 2014: ANIK, JAKK, ZAGG, PLUG, TASR, ANF Moving Higher, FST, UTIW, SEAC, FSLR, DWA Lower

    Benzinga | Feb. 26, 2014 | 09:40AM EST
  12. Morning Market Losers

    Benzinga | Jan. 14, 2014 | 10:02AM EST
  13. Morning Market Movers

    Benzinga | Jan. 13, 2014 | 09:54AM EST
  14. Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors

    Benzinga | Aug. 7, 2013 | 08:01AM EST
  15. UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug

    Benzinga | Dec. 28, 2012 | 03:47AM EST
Trading Center